IQVIA Holdings Inc. (NYSE:IQV) Receives $249.05 Average Target Price from Analysts

IQVIA Holdings Inc. (NYSE:IQV) has earned an average recommendation of “Moderate Buy” from the twenty-one analysts that are covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $249.05.

A number of equities research analysts have recently issued reports on the stock. Bank of America reduced their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Stephens assumed coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Morgan Stanley boosted their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Finally, Robert W. Baird reduced their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IQV. Assetmark Inc. raised its stake in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of IQVIA in the third quarter valued at approximately $230,000. Huntington National Bank increased its stake in shares of IQVIA by 7.4% in the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after buying an additional 56 shares during the period. Empowered Funds LLC increased its stake in shares of IQVIA by 33.9% in the third quarter. Empowered Funds LLC now owns 3,437 shares of the medical research company’s stock valued at $814,000 after buying an additional 871 shares during the period. Finally, Natixis Advisors LLC increased its stake in shares of IQVIA by 26.9% in the third quarter. Natixis Advisors LLC now owns 245,136 shares of the medical research company’s stock valued at $58,090,000 after buying an additional 51,970 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 0.9 %

IQV stock opened at $186.80 on Monday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a fifty day moving average price of $195.71 and a two-hundred day moving average price of $209.36. IQVIA has a one year low of $179.28 and a one year high of $256.29. The stock has a market cap of $32.93 billion, a price-to-earnings ratio of 24.91, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts anticipate that IQVIA will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.